current ART regime to manage virologically suppressed HIV patients
Checking Date & Time
Reading File
Finding Sources
Searching PubMed
"antiretroviral therapy" AND "virologically suppressed" AND switching
Finding Sources
Searching PubMed
"HIV" AND "antiretroviral" AND "maintenance" AND "long-acting"
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
I now have comprehensive information from Harrison's 22E (2025), Goodman & Gilman's, and Katzung's, plus recent PubMed evidence. Let me compile the full answer.
ART Management of Virologically Suppressed HIV Patients
Virologic suppression is defined as a plasma HIV RNA < 50 copies/mL on a stable ART regimen. Once achieved, the goals shift to maintaining suppression, minimizing long-term toxicity, simplifying regimens, and addressing comorbidities — while never compromising the barrier to resistance.
1. Core Principle: Suppression Must Be Maintained Indefinitely
ART does not eradicate HIV. Treatment interruption rapidly reverses viral suppression, accelerates CD4+ decline, and paradoxically increases non-AIDS serious adverse events (cardiovascular, stroke). Unless contraindicated by toxicity, patients on ART should remain on ART indefinitely.
Harrison's Principles of Internal Medicine, 22E (2025) — patients randomized to intermittent therapy had more serious adverse events than those on continuous therapy, demonstrating that some "non-AIDS-defining" events such as MI and stroke are linked to HIV replication.
2. Preferred Maintenance Regimens (DHHS-Aligned)
A. Standard Triple Therapy (preferred first-line backbone)
| Component | Options |
|---|---|
| INSTI (backbone) | Bictegravir (preferred) · Dolutegravir · Raltegravir |
| NRTI dual backbone | TAF/FTC · TDF/FTC · TDF/3TC · ABC/3TC |
Bictegravir/TAF/FTC (Biktarvy) — single-tablet, once daily, very high barrier to resistance, well tolerated. First-line for most virologically suppressed patients who need a switch.
Dolutegravir + 2 NRTIs — e.g., DTG/ABC/3TC (Triumeq) or DTG + TAF/FTC. High genetic barrier. Note: dolutegravir requires dose adjustment (50 mg BID) if co-administered with efavirenz or rifampin.
Boosted darunavir-based regimens — DRV/c or DRV/r + 2 NRTIs: still preferred protease inhibitor strategy per DHHS, particularly in treatment-experienced patients or when INSTI resistance is a concern.
B. Simplified / Streamlined Oral Regimens (switch strategies for suppressed patients)
2-Drug Regimens (INI + NNRTI or NRTI)
Appropriate for virologically suppressed patients who wish to reduce NRTI exposure (renal/bone toxicity, HBV issues):
| Regimen | Indication notes |
|---|---|
| DTG + 3TC (Dovato) | Switch only; no prior INSTI or 3TC resistance; not for HBV co-infection |
| DTG + rilpivirine (Juluca) | Suppressed; CD4 > 200; no prior NNRTI or INSTI resistance; not if VL > 100,000 initially |
| Bictegravir + 3TC | Under investigation |
2-drug switch meta-analysis (PMID: 41189136, 2025): Triple-to-dual switches with integrase inhibitors maintained virologic suppression comparably to triple therapy with a favorable safety profile in suppressed patients.
C. Long-Acting Injectable ART (paradigm shift for virologically suppressed patients)
Cabotegravir (CAB-LA) + Rilpivirine (RPV-LA) — Cabenuva
The most significant advance in maintenance ART for suppressed patients:
| Parameter | Detail |
|---|---|
| Route | IM injection (gluteal) |
| Schedule | Every 4 weeks (monthly) or every 8 weeks (2-monthly) |
| Eligibility | Virologically suppressed (HIV RNA < 50 copies/mL), stable on oral ART, no prior INSTI or NNRTI resistance, no HBV co-infection |
| Oral lead-in | No longer required routinely (previously 28-day oral lead-in was mandated) |
| Loading | CAB 600 mg IM at day 1 and day 29, then 400 mg monthly |
| Mechanism | CAB: INSTI (blocks integration); RPV: NNRTI (non-competitive RT inhibitor) |
| t½ | CAB: 5.6–11.5 weeks; RPV: ~13–28 weeks — drug detectable for >12 months post-injection |
Key advantages:
- Eliminates daily pill burden → dramatically improves adherence and quality of life
- Removes stigma of daily visible pill-taking
Key limitations / contraindications:
- Missed injection > 7 days: resume oral therapy until next scheduled injection
- HBV co-infection: contraindicated for switch from tenofovir-containing regimen — risk of HBV rebound and acute liver injury
- Prior INSTI resistance (especially subtype A1/A6 viruses: higher CAB failure rates)
- Interaction with potent CYP/UGT inducers: rifamycins, carbamazepine, phenytoin, St. John's wort — all contraindicated
Systematic review/NMA (PMID: 40426337, 2025): CAB+RPV injectable had comparable virologic efficacy and resistance-associated mutation rates vs. oral single-tablet INI-based regimens in suppressed patients.
D. Lenacapavir (Sunlenca) — Emerging Role
- Capsid inhibitor — novel mechanism (interferes with nuclear import, assembly, and capsid core formation)
- Currently licensed for heavily treatment-experienced, multidrug-resistant patients; not a first-choice switch agent
- SC injection every 6 months after oral/SC loading — extremely long-acting
- Being actively studied in combination with islatravir for broader maintenance use
3. When to Switch a Suppressed Patient's Regimen
Switching in virologically suppressed patients is warranted when:
| Reason | Preferred switch strategy |
|---|---|
| Simplification / adherence | CAB/RPV injectable or 2-drug oral (DTG+3TC, DTG+RPV) |
| Toxicity (e.g., renal from TDF) | Switch TDF → TAF; or move to NRTI-sparing dual regimen |
| Drug interactions | Replace offending agent while maintaining INSTI backbone |
| Cardiovascular risk (ABC association) | Switch ABC to TAF if high CV risk (still debated) |
| Metabolic (lipids, weight) | INSTI class switch may help; bictegravir or raltegravir have differing metabolic profiles |
| Pregnancy planning | DTG preferred (despite initial neural tube concerns, current evidence strongly supports DTG); avoid EFV |
Before switching, always review:
- Historical resistance testing
- Subtype (subtype A1/A6 increases CAB/RPV failure risk)
- HBV co-infection status
- CD4 nadir and current count
- Prior treatment failures
4. Monitoring in Virologically Suppressed Patients
| Parameter | Frequency |
|---|---|
| HIV RNA (viral load) | Every 3–6 months |
| CD4+ T cell count | Every 6–12 months (if consistently >500, less frequent) |
| Renal function (Cr, eGFR, urinalysis) | Every 6–12 months (more frequent with TDF) |
| Fasting lipids / glucose | Annually (more if on PIs) |
| Bone density (DEXA) | Baseline + as indicated (TDF, post-menopausal women) |
| STI screening | As clinically indicated |
| Liver function (HBV/HCV) | Periodically |
5. Special Situations
HBV co-infection: Must maintain tenofovir (TDF or TAF) in the regimen — discontinuation risks HBV flare. Cannot switch to CAB+RPV or NRTI-sparing regimens without HBV-active coverage.
Pregnancy: Continue ART throughout. DTG is preferred. Avoid EFV in first trimester. For injectable CAB+RPV, data on pregnancy safety are limited.
Older patients: Prefer TAF over TDF (less nephrotoxicity, less bone density loss). Monitor for drug interactions with polypharmacy.
Summary
| Strategy | Best for |
|---|---|
| Bictegravir/TAF/FTC (Biktarvy) | Most suppressed patients needing a simplified, durable, high-barrier oral regimen |
| DTG + 3TC (Dovato) | NRTI-sparing switch in suppressed patients without HBV or prior resistance |
| CAB-LA + RPV-LA (Cabenuva) q4–8 weeks | Suppressed patients seeking injection-based, pill-free maintenance |
| DTG + rilpivirine (Juluca) | Oral 2-drug NRTI-sparing switch in select suppressed patients |
| DRV/c or DRV/r + 2 NRTIs | PI-preferred scenarios or INSTI-resistant cases |
| Lenacapavir-based | Heavily treatment-experienced, MDR-HIV |
Key references:
- Harrison's Principles of Internal Medicine, 22E (2025) — DHHS principles of ART, integrase inhibitors, CAB/RPV
- Goodman & Gilman's Pharmacological Basis of Therapeutics — LA cabotegravir and rilpivirine pharmacology
- Katzung's Basic and Clinical Pharmacology, 16th Ed. — INSTI class, bictegravir, cabotegravir
- Triple-to-dual INSTI switch meta-analysis (PMID 41189136, 2025)
- CAB+RPV vs. oral STR network meta-analysis (PMID 40426337, 2025)
can you provide drug class from each?
Based on the information already in our conversation context, here is the drug class breakdown for each agent mentioned:
Drug Classes of ART Agents in Virologically Suppressed HIV Management
Integrase Strand Transfer Inhibitors (INSTIs)
Mechanism: Block HIV integrase enzyme → prevent integration of proviral DNA into host cell genome
| Drug | Notes |
|---|---|
| Bictegravir | Available only as BIC/TAF/FTC (Biktarvy); very high barrier to resistance |
| Dolutegravir | High barrier to resistance; dose adjustment needed with efavirenz/rifampin |
| Cabotegravir | Long-acting injectable (also oral); structural analogue of dolutegravir |
| Raltegravir | First-in-class INSTI; lower barrier to resistance than DTG/BIC |
| Elvitegravir | Always given with cobicistat booster; not recommended if eGFR < 70 mL/min |
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs/NtRTIs)
Mechanism: Phosphorylated to active form → competitive inhibition of reverse transcriptase → chain termination; active against HIV-1, HIV-2, and some HBV
| Drug | Notes |
|---|---|
| Tenofovir alafenamide (TAF) | Prodrug; less renal and bone toxicity than TDF |
| Tenofovir disoproxil fumarate (TDF) | Prodrug; nephrotoxicity and bone density loss with chronic use |
| Emtricitabine (FTC) | Cytidine analogue; generally nontoxic; active against HBV |
| Lamivudine (3TC) | Cytidine analogue; essentially nontoxic; active against HBV |
| Abacavir (ABC) | Guanosine analogue; risk of fatal hypersensitivity — requires HLA-B*5701 screening |
| Zidovudine (AZT) | Thymidine analogue; bone marrow toxicity; largely replaced in modern regimens |
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Mechanism: Non-competitive, direct binding to RT allosteric site → conformational change → inhibits RT; HIV-1 specific (NOT active against HIV-2)
| Drug | Notes |
|---|---|
| Rilpivirine | Long-acting injectable formulation available (with CAB); QT prolongation risk |
| Doravirine | Well tolerated; fewer CNS and metabolic effects than older NNRTIs |
| Efavirenz | CNS toxicity common; inducer of CYP enzymes; largely replaced |
| Nevirapine | Autoinducer; risk of Stevens-Johnson syndrome and hepatitis |
Protease Inhibitors (PIs)
Mechanism: Inhibit HIV aspartyl protease → prevent cleavage of gag-pol polyprotein → immature, non-infectious virions
| Drug | Notes |
|---|---|
| Darunavir (DRV) | Preferred PI; always boosted with ritonavir (DRV/r) or cobicistat (DRV/c) |
| Ritonavir | Used at sub-therapeutic dose as pharmacokinetic booster (potent CYP3A4/2D6 inhibitor); not used as standalone ART |
| Atazanavir | Available with cobicistat boost; inhibits tubular creatinine secretion |
Entry Inhibitors
Mechanism: Block HIV attachment, co-receptor binding, or membrane fusion
| Drug | Class subdivision | Notes |
|---|---|---|
| Maraviroc | CCR5 antagonist | Only effective against CCR5-tropic virus; requires tropism assay before use |
| Enfuvirtide (T-20) | Fusion inhibitor | SC injection; rarely used now |
| Ibalizumab | Anti-CD4 monoclonal antibody | IV infusion; for multidrug-resistant HIV |
| Fostemsavir | Attachment inhibitor (gp120) | For heavily treatment-experienced patients |
Capsid Inhibitor
Mechanism: Binds p24 capsid hexamer interface → disrupts nuclear import, viral assembly, and capsid core formation (multi-step inhibition)
| Drug | Notes |
|---|---|
| Lenacapavir | SC injection every 6 months; currently for MDR, treatment-experienced patients; being studied for broader use |
Pharmacokinetic Enhancers ("Boosters")
Not antiretrovirals themselves — inhibit CYP3A4/P-gp to increase plasma concentrations of co-administered drugs
| Drug | Notes |
|---|---|
| Ritonavir (low dose) | Boosts DRV, ATV, lopinavir; potent CYP3A4/2D6 inhibitor |
| Cobicistat | Boosts DRV, ATV, elvitegravir; also inhibits renal tubular creatinine secretion → falsely elevates serum creatinine |
Quick Reference: Common Regimens by Class Combination
| Regimen | INSTI | NRTI×2 | Other |
|---|---|---|---|
| Biktarvy | Bictegravir | TAF + FTC | — |
| Dovato | Dolutegravir | 3TC | — (2-drug) |
| Juluca | Dolutegravir | — | Rilpivirine (NNRTI) |
| Cabenuva (injectable) | Cabotegravir | — | Rilpivirine (NNRTI) |
| Triumeq | Dolutegravir | ABC + 3TC | — |
| Symtuza | — | TAF + FTC | DRV/c (PI + booster) |
This is a shared conversation. Sign in to Orris to start your own chat.